Human Microbiome Market

Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic / Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) & Region - Global Forecasts to 2029

Report Code: BT 2711 Apr, 2022, by marketsandmarkets.com

The global Human Microbiome Market in terms of revenue was estimated to be worth $269 million in 2023 and is poised to reach $1,370 million by 2029, growing at a CAGR of 31.1% from 2023 to 2029. The market's growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is also expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth.

Human Microbiome Market

To know about the assumptions considered for the study, Request for Free Sample Report

Human Microbiome Market Dynamics

Drivers: Increasing focus on human microbiome therapeutics development

Human gut microbiomes play a major role in improving the efficacy of therapeutic compounds. Over the years, studies have shown that the right combination of microbes in the human body is beneficial for treating different conditions. This association between microbes and specific disease states could generate new opportunities for drug developers (or vaccine manufacturers). Microbes are rich sources of enzymes, owing to which they can be used in various therapeutic applications, such as the search for novel therapies.

In the last decade, microbiome therapy has gained widespread importance. During a 10-year timespan (fiscal years 2007–2016), the National Institutes of Health (NIH) invested USD 215 million on the Human Microbiome Project (HMP) and USD 728 million on extramural human microbiome research activities outside of the HMP over fiscal years 2012–2016. Similarly, the European Commission established Metagenomics of the Human Intestinal Tract project (MetaHIT), which is mainly focused on gut bacteria. From 2008 to 2012, ~USD 15 million was invested in this project. From 2012 to 2018 ~USD 14 million (EUR 12 million) was invested in MetaCardis (Metagenomics in Cardiometabolic Diseases), which is a major EU-funded research project that investigated the role of gut microbes in cardiometabolic diseases (CMDs). Similarly, Horizon 2020 is one of the biggest EU Research and Innovation programs with funding of nearly USD 96.9 million (€80 billion) available over seven years (2014 to 2020).

Many human microbiome-based product companies are awarded funds to accelerate the development of therapeutic drugs. For instance, in 2020, Vedanta Biosciences (US) received funding from the Biomedical Advanced Research and Development Authority (BARDA) of USD 7.4 million, with the potential for an additional USD 69.5 million to advance the clinical development of VE303 for high-risk Clostridioides difficile infection (CDI). Similarly, in 2020, Finch Therapeutics (US) raised USD 90 million in Series D financing from new and existing investors for the development of CP101 through the final stages of clinical development and regulatory submission in Clostridioides difficile infection. The funding will also be used to advance its platform and pipeline, including the initiation of Phase 1b studies evaluating FIN-211 for autism spectrum disorder (ASD) and CP101 for chronic hepatitis B (HBV). Similar funding and investments focusing on microbiome research for therapeutics development are expected to propel the human microbiome market forward in the coming years.

Opportunities: Increasing collaborations between public-private organizations

With several small innovative players operating in the market, there are various high-growth opportunities for key stakeholders to buy out companies so as to study microbiomes in the hope of identifying new drugs and drug targets for various indications, such as obesity, liver disorders, diabetes, and metabolic disorders. Many market leaders are focusing on strategic collaborations and partnerships to increase their product pipelines through well-organized research and development techniques. In the last two years, there have been several collaborations and partnerships involving major companies.

Challenges: Government regulations

The FDA has not approved any probiotics as a live biotherapeutic product (a biological product other than a vaccine that contains live organisms used to prevent or treat a disease or condition in humans). However, there are FDA-regulated foods, including dietary supplements, containing probiotics that are legally available, though these products cannot be lawfully marketed to cure, mitigate, treat, or prevent any diseases.

Probiotic supplements are being aggressively marketed in retail stores and over the Internet. Although no probiotic has been approved by the FDA for therapeutic purposes as of now, some are undergoing clinical trials and may soon be marketed as biologics or other drugs. The current FDA regulatory requirements are not customised for probiotics. Looking at the future market potential for probiotics, there is a possibility that the FDA may come up with certain regulations for them, which will require research/clinical trials. It has been discussed that probiotics that make drug claims should be exposed to the same requirements as other drugs under the Abbreviated New Drug Application (ANDA) process. This will also allow probiotics to be excused from Phase I trials, the first step in clinical testing, and will have adequate evidence of safety. This may hamper the growth of the human microbiome market since big investors will have to invest more in R&D.

The FDA is considering changing the way it characterises probiotics. This will help reduce the number of unsubstantiated probiotic claims, help consumers make informed decisions, and encourage more research on probiotics. Small molecules, such as those developed by Microbiome Therapeutics, may be able to go through the standard drug regulatory pathway. However, there may be a different or new set of regulatory hurdles for genetically modified bacteria. Other issues, including intellectual property rights for naturally occurring bacteria, may also restrict the launch of new products in the market.

Restraints: Barriers in proving the causal link between dysbiosis and diseases

The human body is home to a diverse community of symbiotic, commensal, and pathogenic microorganisms, collectively known as the microbiota. According to various studies, only 30-40 species of microbiota are shared by individuals. Analyzing specific bacteria from among trillions of species can be a highly challenging task. High-throughput omics technologies can identify the exact bacterial species involved and provide an understanding of how homeostasis between humans and microbes is maintained. According to human microbiome research, dysbiosis of microbiomes results in some of the most chronic and lifestyle diseases, such as obesity, diabetes, and various digestive disorders.

The current approaches for identifying microbial markers for diagnostic purposes need to rely on comparisons with parallel control groups of healthy individuals. Selecting the correct microbial chassis for a microbiota-based therapeutic is challenging, as it is difficult to predict which microbe is best suited for any given application.

While studies have suggested that changes in gut microbiota composition are associated with disease conditions, a direct causal relationship in humans remains debatable. The cause-effect relationship between microbiota dysbiosis and diseases relies mainly on data from experimental models, which may not be true for each individual.

The therapeutics segment to account for the largest share of the human microbiome market in 2023

Based on application, the global market is segmented into therapeutics and diagnostics. The therapeutics segment to account for the largest share of the market in 2023. The increase in funding for R&D into microbiome-based therapies worldwide is the major factor driving the growth of this application segment. In addition, technological advancements, the increasing number of clinical trials for the diagnostics segment, and growing collaborations between key market players and research institutes are also supporting market growth.

By disease, the infectious diseases segment is expected to grow at the highest CAGR during the forecast period.

Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. The infectious disease segment is expected to register the highest growth rate during the forecast period. Increasing cognizance of the ill-effects of antibiotic use on the natural flora (such as disruptions) has highlighted the need for specific bacterial-targeted therapy for infectious diseases. The rising incidence of infections due to microbial dysbiosis, as a result of antibiotic treatment, and the increasing number of clinical trials for the development of target-specific microbiome-based therapies are the major factors driving the growth of this segment.

By technology, the genomics segment is expected to grow at the highest CAGR during the forecast period.

On the basis of technology, the human microbiome research spending market is segmented into genomics, proteomics, and metabolomics. The genomics segment is expected to register the highest CAGR during the forecast period. The increasing number of projects funded by private and government bodies is a key driver for the genomics market.

North America accounted for the largest share of the human microbiome market.

In 2023, North America accounted for the largest share of the overall market, followed by Europe. Factors such as the increasing incidences of lifestyle diseases, rising awareness of preventive healthcare, availability of funding for microbiome research, and the increasing number of microbiome research and clinical activities are responsible for driving the growth of the market in North America.

Human Microbiome Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The major players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics (US) 4D Pharma (UK), Ferring Pharmaceuticals (Switzerland), ViThera Pharmaceuticals (US), Second Genome (US), Vedanta BioSciences (US), and Synlogic (US).

Human Microbiome Market Report Scope

Report Metric

Details

Market Revenue in 2023

$269 million

Estimated Value by 2029

$1,370 million

Growth Rate

Poised to grow at a CAGR of 31.1%

Largest Share Segments

Based On Application - The therapeutics segment to account for the largest share

Based On Disease - Infectious diseases segment is expected to grow at the highest CAGR

By Technology - Genomics segment is expected to grow at the highest CAGR

Market Report Segmentation

Product, Application, Disease, Research Technology and Regional & Global Level 

Growth Drivers

  • Increasing focus on human microbiome therapeutics development

Growth Opportunities

  • Increasing collaborations between public-private organizations

Geographies covered

North America, Europe, APAC, MEA, and Latin America

Human Microbiome Market Report Segmentation

Based on product

  • Probiotics
  • Prebiotics
  • Diagnostic Tests
  • Drugs
  • Other Products

Based on disease

  • Infectious Diseases
  • Endocrine and Metabolic Disorders
  • Gastrointestinal Diseases
  • Cancer
  • Other Diseases (cardiovascular diseases, neurological disorders, dermatology diseases, immune-modulated disorders, and hematological disorders.

Based on application

  • Therapeutics
  • Diagnostics

Based on type

  • FMT
  • Peptide
  • Live Biotherapeutic Product
  • Others

Based on region

  • North America
    • US
    • Canada
  • Europe 
  • Asia Pacific
  • Rest of the World (RoW)

Based on the technology

  • Genomics
    • Sequencing
      • 16s rRNA sequencing method
      • Whole-genome sequencing method
      • Other Sequencing methods (shotgun metagenomic sequencing, transcriptomics, and targeted sequencing.)
    • Other Genomic Technologies (Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH), and DNA Microarrays)
  • Proteomics
  • Metabolomics

Recent Developments:

  • In 2022, OptiBiotix Health Plc. signed an exclusive sales and distribution agreement with Nahdi Medical Co. To help tackle the obesity epidemic, the company’s GoFigure and SlimBiome Medical weight management products will be available in the KSA from early 2022 through the new agreement with Nahdi. 
  • In 2020, 4D pharma merged with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease.
  • In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 26)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 MARKETS COVERED FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET
           1.3.3 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME RESEARCH SPENDING MARKET)
           1.3.4 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME MARKET)
    1.4 CURRENCY
    1.5 STAKEHOLDERS
    1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 32)
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY SOURCES
                    FIGURE 1 BREAKDOWN OF PRIMARIES: GLOBAL MARKET
    2.2 MARKET DATA ESTIMATION AND TRIANGULATION
           FIGURE 2 DATA TRIANGULATION METHODOLOGY
           2.2.1 MARKET ESTIMATION METHODOLOGY
                    FIGURE 3 MARKET SIZE ESTIMATION APPROACH: R&D SPENDING ANALYSIS-BASED ESTIMATION (FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET)
                    FIGURE 4 HUMAN MICROBIOME RESEARCH SPENDING MARKET SIZE (USD MILLION): FINAL MARKET SIZE
           2.2.2 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
                    FIGURE 5 FINAL CAGR PROJECTIONS (2023−2029)
           2.2.3 POTENTIAL MARKET SIZE CALCULATION FOR GLOBAL MARKET
                    FIGURE 6 GLOBAL MARKET SIZE BASED ON EPIDEMIOLOGY APPROACH
    2.3 INSIGHTS FROM PRIMARIES
           FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
    2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. - 39)
    FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
    FIGURE 9 GLOBAL MARKET SHARE, BY APPLICATION, 2029
    FIGURE 10 GLOBAL MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION)
    FIGURE 11 GEOGRAPHICAL SNAPSHOT OF GLOBAL MARKET

4 PREMIUM INSIGHTS (Page No. - 42)
    4.1 HUMAN MICROBIOME: MARKET OVERVIEW
           FIGURE 12 INCREASING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE MARKET GROWTH
    4.2 HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2029)
           FIGURE 13 FMT TO DOMINATE GLOBAL MARKET IN 2023
    4.3 NORTH AMERICA: GLOBAL MARKET, BY PRODUCT & APPLICATION (2023)
    4.4 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY (2023–2029)
           FIGURE 14 CHINA TO GROW AT THE HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 45)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Rising industry-academia collaborations for microbiome research
                    5.2.1.2 Increasing focus on human microbiome therapeutics development
                    5.2.1.3 Human microbiome as a validated target for drug development
                    5.2.1.4 Development of human microbiome-based tests for early disease detection & diagnosis
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 Barriers in proving the causal link between dysbiosis and diseases
                    5.2.2.2 Negative clinical data will adversely impact public perception of microbiomes
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 Increasing collaborations between public-private organizations
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Government regulations
                    5.2.4.2 Lack of expertise and inadequate research
    5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE GLOBAL MARKET
    5.4 REGULATORY ANALYSIS
           5.4.1 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED DRUGS
           5.4.2 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED FOODS
    5.5 PATENT ANALYSIS

6 HUMAN MICROBIOME MARKET, BY APPLICATION (Page No. - 56)
    6.1 INTRODUCTION
           TABLE 1 GLOBAL MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
    6.2 THERAPEUTIC APPLICATIONS
           6.2.1 AVAILABILITY OF FUNDING FOR MICROBIOME-BASED THERAPEUTIC PRODUCTS DEVELOPMENT TO DRIVE MARKET GROWTH
                    TABLE 2 GLOBAL MARKET FOR THERAPEUTICS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 3 NORTH AMERICA: MARKET FOR THERAPEUTICS, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 4 EUROPE: MARKET FOR THERAPEUTICS, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 5 ASIA PACIFIC: MARKET FOR THERAPEUTICS, BY COUNTRY 2023–2029 (USD MILLION)
    6.3 DIAGNOSTIC APPLICATIONS
           6.3.1 INCREASING FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET GROWTH
                    TABLE 6 GLOBAL MARKET FOR DIAGNOSTICS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 7 NORTH AMERICA: MARKET FOR DIAGNOSTICS, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 8 EUROPE: MARKET FOR DIAGNOSTICS, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 9 ASIA PACIFIC: MARKET FOR DIAGNOSTICS, BY COUNTRY 2023–2029 (USD MILLION)

7 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY (Page No. - 62)
    7.1 INTRODUCTION
           TABLE 10 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION)
    7.2 GENOMICS
           TABLE 11 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY TYPE, 2021–2029 (USD MILLION)
           TABLE 12 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY REGION, 2021–2029 (USD MILLION)
           TABLE 13 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
           TABLE 14 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
           TABLE 15 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
           7.2.1 SEQUENCING
                    TABLE 16 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 17 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 18 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 19 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 20 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY METHOD, 2021–2029 (USD MILLION)
                    7.2.1.1 16S rRNA Sequencing Method
                               7.2.1.1.1 Cost-effectiveness to propel identification of bacterial strains
                                            TABLE 21 16S RRNA SEQUENCING METHOD, BY REGION, 2021–2029 (USD MILLION)
                                            TABLE 22 NORTH AMERICA: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2018–2025 (USD MILLION)
                                            TABLE 23 EUROPE: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
                                            TABLE 24 ASIA PACIFIC: 16S RRNA SEQUENCING METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
                    7.2.1.2 Whole-Genome Sequencing (WGS)Method
                               7.2.1.2.1 WGS to generate accurate reference genomes for microbial identification
                                            TABLE 25 WGS METHOD, BY REGION, 2021–2029 (USD MILLION)
                                            TABLE 26 NORTH AMERICA: WGS METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
                                            TABLE 27 EUROPE: WGS METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
                                            TABLE 28 ASIA PACIFIC: WGS METHOD, BY COUNTRY, 2021–2029 (USD MILLION)
                    7.2.1.3 Other Sequencing Methods
                               TABLE 29 OTHER SEQUENCING METHODS, BY REGION, 2021–2029 (USD MILLION)
                               TABLE 30 NORTH AMERICA: OTHER SEQUENCING METHODS, BY COUNTRY, 2021–2029 (USD MILLION)
                               TABLE 31 EUROPE: OTHER SEQUENCING METHODS, BY COUNTRY, 2021–2029 (USD MILLION)
                               TABLE 32 ASIA PACIFIC: OTHER SEQUENCING METHODS BY COUNTRY, 2021–2029 (USD MILLION)
           7.2.2 OTHER GENOMIC TECHNOLOGIES
                    TABLE 33 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 34 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 35 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION)
    7.3 PROTEOMICS
           7.3.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMIC TECHNOLOGIES TO DRIVE MARKET GROWTH
                    TABLE 37 PROTEOMICS, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 38 NORTH AMERICA: PROTEOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 39 EUROPE: PROTEOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 40 ASIA PACIFIC: PROTEOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
    7.4 METABOLOMICS
           7.4.1 ADVANTAGES OF METABOLOMICS OVER GENOMICS AND PROTEOMICS TO DRIVE MARKET GROWTH
                    TABLE 41 METABOLOMICS, BY REGION, 2021–2029 (USD MILLION)
                    TABLE 42 NORTH AMERICA: METABOLOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 43 EUROPE: METABOLOMICS, BY COUNTRY, 2021–2029 (USD MILLION)
                    TABLE 44 ASIA PACIFIC: METABOLOMICS, BY COUNTRY, 2021–2029 (USD MILLION)

8 HUMAN MICROBIOME MARKET, BY TYPE (Page No. - 76)
    8.1 INTRODUCTION
           TABLE 45 GLOBAL MARKET, BY TYPE, 2023–2029 (USD MILLION)
    8.2 MICROBIOME CONSORTIA TRANSPLANTATION (FMT)
           8.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR C. DIFFICILE INFECTION TREATMENT TO AUGMENT SEGMENTAL GROWTH
                    TABLE 46 GLOBAL MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY REGION, 2023–2029 (USD MILLION)
                    TABLE 47 NORTH AMERICA: MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 48 EUROPE: MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 49 ASIA PACIFIC: MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023–2029 (USD MILLION)
    8.3 PEPTIDE
           8.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO GROW IN FORECAST PERIOD
                    TABLE 50 GLBOAL MARKET FOR PEPTIDE, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 51 NORTH AMERICA: MARKET FOR PEPTIDE, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 52 EUROPE: MARKET FOR PEPTIDE, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 53 ASIA PACIFIC: MARKET FOR PEPTIDE, BY COUNTRY 2023–2029 (USD MILLION)
    8.4 LIVE BIOTHERAPEUTIC PRODUCT
           8.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST SEGMENTAL GROWTH
                    TABLE 54 GLOBAL MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 55 NORTH AMERICA: MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 56 EUROPE: MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 57 ASIA PACIFIC: MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023–2029 (USD MILLION)

    8.5 OTHERS
           8.5.1 INCREASING FOCUS ON SMALL MOLECULES TO PROPEL SEGMENTAL GROWTH
                    TABLE 58 GLOBAL MARKET FOR OTHERS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 59 NORTH AMERICA: MARKET FOR OTHERS, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 60 EUROPE: MARKET FOR OTHERS, BY COUNTRY 2023–2029 (USD MILLION)
                    TABLE 61 ASIA PACIFIC: MARKET FOR OTHERS, BY COUNTRY 2023–2029 (USD MILLION)

9 HUMAN MICROBIOME MARKET, BY PRODUCT (Page No. - 85)
    9.1 INTRODUCTION
           TABLE 62 GLOBAL MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
    9.2 DRUGS
           9.2.1 INCREASING NUMBER OF MICROBIOME-BASED DRUGS IN PIPELINE TO DRIVE SEGMENT GROWTH
                    TABLE 63 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 64 NORTH AMERICA: MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 65 EUROPE: MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 66 ASIA PACIFIC: MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION)
    9.3 DIAGNOSTIC TESTS
           9.3.1 GROWING CONSUMER AWARENESS ABOUT MICROBIOME- BASED TESTS TO DRIVE SEGMENT GROWTH
                    TABLE 67 GLOBAL MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 68 NORTH AMERICA: MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 69 EUROPE: MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 70 ASIA PACIFIC: MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION)
    9.4 PROBIOTICS
           9.4.1 ONGOING RESEARCH PROMOTING CREDIBILITY REGARDING HEALTH CLAIMS AND SAFETY OF PROBIOTICS
                    TABLE 71 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 72 NORTH AMERICA: MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 73 EUROPE: MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 74 ASIA PACIFIC: MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
    9.5 PREBIOTICS
           9.5.1 DEVELOPMENT OF TARGETED PREBIOTICS IN ENHANCING GUT MICROBIOTA TO DRIVE SEGMENT GROWTH
                    TABLE 75 GLOBAL MARKET FOR PREBIOTICS, BY REGION, 2023–2029 (USD MILLION)
                    TABLE 76 NORTH AMERICA: MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 77 EUROPE: MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
                    TABLE 78 ASIA PACIFIC: MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION)
    9.6 OTHER PRODUCTS
           TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2029 (USD MILLION)
           TABLE 80 NORTH AMERICA: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
           TABLE 81 EUROPE: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)
           TABLE 82 ASIA PACIFIC: MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION)

10 HUMAN MICROBIOME MARKET, BY DISEASE (Page No. - 96)
     10.1 INTRODUCTION
             TABLE 83 GLOBAL MARKET, BY DISEASE, 2023–2029 (USD MILLION)
     10.2 INFECTIOUS DISEASES
             10.2.1 INCREASING NUMBER OF CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO DRIVE SEGMENT GROWTH
                        TABLE 84 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES
                        TABLE 85 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2029 (USD MILLION)
                        TABLE 86 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
                        TABLE 87 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
                        TABLE 88 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
     10.3 GASTROINTESTINAL DISEASES
             10.3.1 INCREASING NUMBER OF CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO DRIVE SEGMENT GROWTH
                        TABLE 89 GLOBAL MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2029 (USD MILLION)
                        TABLE 90 NORTH AMERICA: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
                        TABLE 91 EUROPE: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
                        TABLE 92 ASIA PACIFIC: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
     10.4 ENDOCRINE & METABOLIC DISORDERS
             10.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO DRIVE SEGMENT GROWTH
                        TABLE 93 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR METABOLIC DISEASES
                        TABLE 94 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION)
                        TABLE 95 NORTH AMERICA: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
                        TABLE 96 EUROPE: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
                        TABLE 97 ASIA PACIFIC: MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)
     10.5 CANCER
             10.5.1 MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY IN TREATMENT OF PELVIC AND COLON CANCER
                        TABLE 98 GLBOAL MARKET FOR CANCER, BY REGION, 2023–2029 (USD MILLION)
                        TABLE 99 NORTH AMERICA: MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)
                        TABLE 100 EUROPE: MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)
                        TABLE 101 ASIA PACIFIC: MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION)
     10.6 OTHER DISEASES
             TABLE 102 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2029 (USD MILLION)
             TABLE 103 NORTH AMERICA: MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
             TABLE 104 EUROPE: MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)
             TABLE 105 ASIA PACIFIC: MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)

11 HUMAN MICROBIOME MARKET, BY REGION (Page No. - 107)
     11.1 INTRODUCTION
             TABLE 106 GLOBAL MARKET, BY REGION, 2023–2029 (USD MILLION)
     11.2 NORTH AMERICA
             FIGURE 16 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT
             TABLE 107 NORTH AMERICA: MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
             TABLE 108 NORTH AMERICA: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
             TABLE 109 NORTH AMERICA: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             TABLE 110 NORTH AMERICA: MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Increasing investments by NIH in support of microbiome research to drive market growth
                                     TABLE 111 US: MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                     TABLE 112 US: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                     TABLE 113 US: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Increasing government support and funds to support market growth
                                     TABLE 114 INDICATIVE LIST OF PROJECTS ON HUMAN MICROBIOME IN 2018
                                     TABLE 115 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                     TABLE 116 CANADA: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                     TABLE 117 CANADA: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
     11.3 EUROPE
             FIGURE 17 EUROPE: MARKET SNAPSHOT
             TABLE 118 EU MICROBIOME PROJECT
             TABLE 119 EUROPE: MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
             TABLE 120 EUROPE: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
             TABLE 121 EUROPE: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             TABLE 122 EUROPE: MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Extended applications of microbiome research to therapeutic areas to boost adoption of microbiome-based products
                                     TABLE 123 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                     TABLE 124 GERMANY: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                     TABLE 125 GERMANY: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Increasing focus on microbiome-based products development to drive market growth
                                     TABLE 126 UK: MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                     TABLE 127 UK: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                     TABLE 128 UK: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Increasing funding to boost microbiome-based products development
                                     TABLE 129 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                     TABLE 130 FRANCE: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                     TABLE 131 FRANCE: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             11.3.4 ROE
                        TABLE 132 ROE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                        TABLE 133 ROE: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                        TABLE 134 ROE: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
     11.4 ASIA PACIFIC
             FIGURE 18 ASIA PACIFIC: MARKET SNAPSHOT
             TABLE 135 ASIA PACIFIC: MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
             TABLE 136 ASIA PACIFIC: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
             TABLE 137 ASIA PACIFIC: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             TABLE 138 ASIA PACIFIC: MARKET, BY COUNTRY, 2023–2029 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Large number of human microbiome research studies to drive market growth
                                     TABLE 139 INDICATIVE LIST OF HUMAN MICROBIOME RESEARCH STUDIES CONDUCTED IN CHINA
                                     TABLE 140 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                     TABLE 141 CHINA: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                     TABLE 142 CHINA: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Increasing focus on funding for microbiome-based products to drive market growth
                                     TABLE 143 JAPAN: MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                     TABLE 144 JAPAN: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                     TABLE 145 JAPAN: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Government funding to drive microbiome-based products development
                                     TABLE 146 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                                     TABLE 147 INDIA: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                                     TABLE 148 INDIA: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
             11.4.4 REST OF ASIA PACIFIC
                        TABLE 149 ROAPAC: MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
                        TABLE 150 ROAPAC: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
                        TABLE 151 ROAPAC: MARKET, BY DISEASE, 2023-2029 (USD MILLION)
     11.5 REST OF THE WORLD (ROW)
             TABLE 152 ROW: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)
             TABLE 153 ROW: MARKET, BY APPLICATION, 2023–2029 (USD MILLION)
             TABLE 154 ROW: MARKET, BY DISEASE, 2023-2029 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 133)
     12.1 OVERVIEW
     12.2 PRODUCT TYPE FOOTPRINT OF COMPANIES
             TABLE 155 PRODUCT TYPE PORTFOLIO ANALYSIS: HUMAN MICROBIOME MARKET (2021)
     12.3 CLINICAL PHASE FOOTPRINT OF COMPANIES
             TABLE 156 CLINICAL PHASE FOOTPRINT OF COMPANIES: GLOBAL MARKET (2021)
     12.4 DISEASE FOOTPRINT OF COMPANIES
             TABLE 157 DISEASE FOOTPRINT OF COMPANIES: GLOBAL MARKET (2021)
     12.5 COMPETITIVE SCENARIO
             TABLE 158 GLOBAL MARKET: KEY DEALS, JANUARY 2020–JANUARY 2021

13 COMPANY PROFILES (Page No. - 137)
     13.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 
             13.1.1 ENTEROME
                        TABLE 159 ENTEROME: BUSINESS OVERVIEW
             13.1.2 SERES THERAPEUTICS
                        TABLE 160 SERES THERAPEUTICS: BUSINESS OVERVIEW
                        FIGURE 19 SERES THERAPEUTICS: COMPANY SNAPSHOT (2021)
             13.1.3 4D PHARMA PLC
                        TABLE 161 4D PHARMA PLC: BUSINESS OVERVIEW
                        FIGURE 20 4D PHARMA PLC: COMPANY SNAPSHOT (2020)
             13.1.4 INTERNATIONAL FLAVORS & FRAGRANCES INC.
                        TABLE 162 INTERNATIONAL FLAVORS & FRAGRANCES INC.: BUSINESS OVERVIEW
                        FIGURE 21 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2021)
             13.1.5 OPTIBIOTIX HEALTH PLC.
                        TABLE 163 OPTIBIOTIX HEALTH PLC.: BUSINESS OVERVIEW
                        FIGURE 22 OPTIBIOTIX HEALTH PLC.: COMPANY SNAPSHOT (2020)
                        TABLE 164 PRODUCT LAUNCHES
             13.1.6 SYNLOGIC, INC.
                        TABLE 165 SYNLOGIC: BUSINESS OVERVIEW
                        FIGURE 23 SYNLOGIC, INC.: COMPANY SNAPSHOT (2020)
             13.1.7 SECOND GENOME INC.
                        TABLE 166 SECOND GENOME INC.: BUSINESS OVERVIEW
             13.1.8 VEDANTA BIOSCIENCES, INC.
                        TABLE 167 VEDANTA BIOSCIENCES, INC.: BUSINESS OVERVIEW
             13.1.9 FERRING PHARMACEUTICALS
                        TABLE 168 FERRING PHARMACEUTICALS: BUSINESS OVERVIEW
             13.1.10 EVELO BIOSCIENCES, INC.
                        TABLE 169 EVELO BIOSCIENCES: BUSINESS OVERVIEW
                        FIGURE 24 EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020)
             13.1.11 BIOMX
                        TABLE 170 BIOMX: BUSINESS OVERVIEW
                        FIGURE 25 BIOMX: COMPANY SNAPSHOT (2020)
             13.1.12 YSOPIA BIOSCIENCE
                        TABLE 171 YSOPIA BIOSCIENCE: BUSINESS OVERVIEW
             13.1.13 KALEIDO BIOSCIENCES, INC.
                        TABLE 172 KALEIDO BIOSCIENCES, INC.: BUSINESS OVERVIEW
                        FIGURE 26 KALEIDO BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020)
             13.1.14 FLIGHTPATH BIOSCIENCES, INC.
                        TABLE 173 FLIGHTPATH BIOSCIENCES, INC.: BUSINESS OVERVIEW
             13.1.15 FINCH THERAPEUTICS GROUP, INC.
                        TABLE 174 FINCH THERAPEUTICS GROUP, INC.: BUSINESS OVERVIEW
                        FIGURE 27 FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2020)
             13.1.16 QUANTBIOME, INC. (DBA OMBRE)
                        TABLE 175 QUANTBIOME, INC.: BUSINESS OVERVIEW
             13.1.17 VIOME LIFE SCIENCES, INC.
                        TABLE 176 VIOME LIFE SCIENCES, INC.: BUSINESS OVERVIEW
             13.1.18 BIOHM HEALTH
                        TABLE 177 BIOHM HEALTH: BUSINESS OVERVIEW
     13.2 OTHER COMPANIES
             13.2.1 DAYTWO
                        TABLE 178 DAYTWO: COMPANY OVERVIEW
             13.2.2 ATLAS BIOMED
                        TABLE 179 ATLAS BIOMED: COMPANY OVERVIEW
             13.2.3 BIONE
                        TABLE 180 BIONE: COMPANY OVERVIEW
             13.2.4 LUXIA SCIENTIFIC
                        TABLE 181 LUXIA SCIENTIFIC: COMPANY OVERVIEW
             13.2.5 METABIOMICS
                        TABLE 182 METABIOMICS: COMPANY OVERVIEW
             13.2.6 SUN GENOMICS
                        TABLE 183 SUN GENOMICS: COMPANY OVERVIEW
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 

14 APPENDIX (Page No. - 182)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This market research study involves the extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global human microbiome market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market prospects. The human microbiome market's size was estimated through various secondary research approaches and triangulated with inputs from primary research.

Secondary Research

The secondary sources referred to for this research study include publications from government sources such as the World Health Organization (WHO), Human Microbiome Project (HMP), Organization for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), Food and Drug Administration (FDA), ClinicalTrials.gov, Expert Interviews, and MarketsandMarkets Analysis; business magazines and research journals; press releases; and trade, business, and professional associations.

Secondary data was collected and analyzed to arrive at the global human microbiome market's overall size, which was validated through primary research.

Primary Research

In the primary research process, various sources from the supply sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, technology & innovation directors, personnel from research organizations, physicians, academic institutes, and related key executives from various key companies and organizations operating in the human microbiome market.

Human Microbiome Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

In this report, the global potential market size for the human microbiome was calculated using the epidemiology approach.

  • Key indications were identified for which microbiome therapy clinical trials are underway
  • For respective disease categories, estimating the potential market for microbiome-based drugs from existing non-microbiome-based drugs market Microbiome therapeutics are likely to be adopted by a set of patients who show side-effects for existing therapies. Therefore, the percentage of the patient population showing some side-effects with existing therapies was identified. This percentage was then applied to the total therapy market to derive the human microbiome's total addressable market.
  • To calculate the total market for microbiome therapy, the penetration rate for microbiome therapies was applied to the total addressable market
  • Primary experts then validated this approach.

Individual shares of each product, disease, region, and application were arrived at based on parameters such as product pipeline, clinical trials progress, target indications, funding scenario, and research intensity in the microbiome.

Data Triangulation

After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides of the human microbiome market.

Report Objectives

  • To define, describe, segment, and forecast the human microbiome market based on product, application, disease, and region
  • To define, describe, segment, and forecast the human microbiome research spending market based on technology
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 and subsegments with respect to individual growth trends, prospects, and contributions to the overall human microbiome market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments concerning four main regions (along with countries), namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (South America, Latin America, and the Middle East & Africa)
  • To strategically analyze the market structure and profile the key players of the global human microbiome market and comprehensively analyze their core competencies2
  • To track and analyze competitive developments such as acquisitions; partnerships, agreements, & collaborations; and product launches in the human microbiome market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs.

The following customization option is available for the report:

Additional Company Profiles

  • Company profiles for five additional companies.
Report Code
BT 2711
Published ON
Apr, 2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Human Microbiome Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback